Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
In China, tislelizumab plus chemotherapy is a cost-effective first-line therapy for unresectable GC/GEJC in both ITT and TAP ≥ 5% subgroups. In the US, tislelizumab plus chemotherapy is not cost-effective.
Authors
- Qinling Jiang
- Qi Ai (ORCID: https://orcid.org/0000-0002-6501-3051)
- Ming Ouyang (ORCID: https://orcid.org/0000-0001-5890-377X)
- W.J. Lang (ORCID: https://orcid.org/0009-0007-3583-9518)
- Wenwen Zhang (ORCID: https://orcid.org/0000-0003-1120-8977)
- Yulong He (ORCID: https://orcid.org/0000-0001-9675-4461)
Institutions
- Nanxi Mountain Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fphar.2024.1461571
- Citations
- 9
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.77